JOHNSON & JOHNSON

NEW BRUNSWICK, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Oct 26, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$761.7M2026 Q3
Positions15
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.98.8%

JOHNSON & JOHNSON reported 15 positions worth $761.7M as of September 30, 2026 (13F filed October 26, 2026). Largest holding: PTGX (45.3%). Biggest move: add CBRS ($13.3M).

10 / 15 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PTGXProtagonist Therapeutics$345.1M45.30%2,449,183——-7.1%
▸ 2 NBTXNanobiotix S.A.$175.2M23.01%5,623,816———
▸ 3 MGTXMeiraGTx$73.1M9.59%6,641,064——-16.5%
▸ 4 RAPPRapport Therapeutics$60.0M7.87%1,784,517——-22.2%
▸ 5 CTNMContineum Therapeutics$26.6M3.49%1,979,173——-26.5%
▸ 6 CBRSCerebras Systems$22.9M3.00%128,649——-38.8%
▸ 7 XNCRXencor$18.7M2.45%748,062——+48.7%
▸ 8 LEGNLegend Biotech$16.2M2.13%814,586——-12.0%
▸ 9 FATEFate Therapeutics$8.0M1.05%3,379,064——-46.0%
▸ 10 CVRXCVRx$7.0M0.93%4,024,861——-65.3%

Pro Feature

The remaining 5 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does JOHNSON & JOHNSON hold as of Q3 2026?

JOHNSON & JOHNSON reported 15 positions worth $761.7M in its Q3 2026 13F filing. Largest positions: PTGX (45.3%), NBTX (23.0%), MGTX (9.6%), RAPP (7.9%) and CTNM (3.5%).

What did JOHNSON & JOHNSON buy in Q3 2026?

Added to: CBRS.

What did JOHNSON & JOHNSON sell in Q3 2026?

JOHNSON & JOHNSON reduced or sold out of no positions in Q3 2026.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.